nach oben

Erschienen in:

17.01.2019 | Review articles

Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials

verfasst von: Dr. T. Zhan, Dr. M. Daniyal, Dr. J. Li, Dr. Y. Mao

Erschienen in: Herz | Sonderheft 1/2020

Einloggen, um Zugang zu erhalten

Abstract

Background

Clinical or subclinical cardiotoxicity is a concern for cancer patients receiving anthracycline-based chemotherapy. Carvedilol is promising for preventing anthracycline-induced cardiotoxicity (AIC). This review appraised the preventive effects of carvedilol against AIC based on randomized controlled trials (RCTs).

Methods

The Cochrane Collaboration Central Register of Controlled Trials, PubMed, and Embase databases were searched from inception to March 27, 2018. RCTs using carvedilol for the prevention of AIC were selected. Risk of bias and methodological quality were assessed. Meta-analysis was conducted, when applicable, for the trial endpoints; otherwise the data were analyzed descriptively.

Results

Nine RCTs comprising 717 patients were selected. The risk of bias was unclear and the methodological quality differed substantially. Data pooling of five eligible studies indicated no decreased mortality in patients receiving carvedilol (risk difference = −0.02, 95% CI: −0.07–0.04, p = 0.57, I² = 44%). The impact on the incidence of left ventricular systolic dysfunction (LVSD) was inconsistently reported but meta-analysis was not applicable due to discordant LVSD definitions. Data pooling of eight studies and a subgroup analysis indicated a higher left ventricular ejection fraction (LVEF) with substantial heterogeneity in the carvedilol group (mean difference [MD] = 5.23, 95% CI: 2.20–8.27, p = 0.0007, I² = 95%, and MD = 4.65, 95% CI: 0.67–8.64, p = 0.02, I² = 90%, respectively). Further analysis of echocardiographic parameters and biomarkers showed weak evidence of improvement in diastolic function and troponin I level by carvedilol administration.

Conclusion

Preventive use of carvedilol in patients undergoing anthracycline-based chemotherapy may be associated with a reduced incidence of LVSD, higher LVEF value, better diastolic function, and lower troponin I level. RCTs with larger sample size and longer follow-up are needed to verify these findings.

Gradishar WJ, Anderson BO, Balassanian R et al (2017) NCCN guidelines insights: breast cancer, version 1.2017. J Natl Compr Canc Netw 15(4):433–451CrossRef

Ogura M, Ishida T, Tsukasaki K et al (2016) Effects of first-line chemotherapy on natural killer cells in adult T‑cell leukemia-lymphoma and peripheral T‑cell lymphoma. Cancer Chemother Pharmacol 78(1):199–207. https://doi.org/10.1007/s00280-016-3070-2CrossRefPubMedPubMedCentral

Hoppe RT, Advani RH, Ai WZ et al (2017) Hodgkin lymphoma version 1.2017, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw 15(5):608–638CrossRef

Horwitz SM, Zelenetz AD, Gordon LI et al (2016) NCCN guidelines insights: non-Hodgkin’s lymphomas, version 3.2016. J Natl Compr Canc Netw 14(9):1067–1079CrossRef

Swain SM, Whaley FS, Ewer MS (2003) Congestive heart failure in patients treated with doxorubicin: a retrospective analysis of three trials. Cancer 97(11):2869–2879. https://doi.org/10.1002/cncr.11407CrossRefPubMed

Wang TJ, Evans JC, Benjamin EJ et al (2003) Natural history of asymptomatic left ventricular systolic dysfunction in the community. Circulation 108(8):977–982. https://doi.org/10.1161/01.cir.0000085166.44904.79CrossRefPubMed

Kremer LC, van der Pal HJ, Offringa M et al (2002) Frequency and risk factors of subclinical cardiotoxicity after anthracycline therapy in children: a systematic review. Ann Oncol 13(6):819–829CrossRef

van Dalen EC, van der Pal HJ, Kok WE et al (2006) Clinical heart failure in a cohort of children treated with anthracyclines: a long-term follow-up study. Eur J Cancer 42(18):3191–3198. https://doi.org/10.1016/j.ejca .2006.08.005CrossRef

Henriksen PA (2017) Anthracycline cardiotoxicity: an update on mechanisms, monitoring and prevention. Heart. https://doi.org/10.1136/heartjnl-2017-312103CrossRefPubMedPubMedCentral

10.

van Dalen EC, Caron HN, Dickinson HO, Kremer LC (2011) Cardioprotective interventions for cancer patients receiving anthracyclines. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD003917.pub4CrossRefPubMedPubMedCentral

11.

Yun S, Vincelette ND, Abraham I (2015) Cardioprotective role of beta-blockers and angiotensin antagonists in early-onset anthracyclines-induced cardiotoxicity in adult patients: a systematic review and meta-analysis. Postgrad Med J 91(1081):627–633. https://doi.org/10.1136/postgradmedj-2015-133535CrossRefPubMed

12.

Cheng J, Kamiya K, Kodama I (2001) Carvedilol: molecular and cellular basis for its multifaceted therapeutic potential. Cardiovasc Drug Rev 19(2):152–171CrossRef

13.

Spallarossa P, Garibaldi S, Altieri P et al (2004) Carvedilol prevents doxorubicin-induced free radical release and apoptosis in cardiomyocytes in vitro. J Mol Cell Cardiol 37(4):837–846. https://doi.org/10.1016/j.yjmcc.2004.05.024CrossRefPubMed

14.

Chen YL, Chung SY, Chai HT et al (2015) Early administration of carvedilol protected against doxorubicin-induced cardiomyopathy. J Pharmacol Exp Ther 355(3):516–527. https://doi.org/10.1124/jpet.115.225375CrossRefPubMed

15.

Arozal W, Watanabe K, Veeraveedu PT et al (2010) Protective effect of carvedilol on daunorubicin-induced cardiotoxicity and nephrotoxicity in rats. Toxicology 274(1–3):18–26. https://doi.org/10.1016/j.tox.2010.05.003CrossRefPubMed

16.

Cheuk DK, Sieswerda E, van Dalen EC et al (2016) Medical interventions for treating anthracycline-induced symptomatic and asymptomatic cardiotoxicity during and after treatment for childhood cancer. Cochrane Database Syst Rev. https://doi.org/10.1002/14651858.CD008011.pub3CrossRefPubMedPubMedCentral

17.

Shaikh F, Dupuis LL, Alexander S et al (2016) Cardioprotection and second malignant neoplasms associated with dexrazoxane in children receiving anthracycline chemotherapy: a systematic review and Meta-analysis. J Natl Cancer Inst 108(4). https://doi.org/10.1093/jnci/djv357CrossRefPubMed

18.

Abdel-Qadir H, Ong G, Fazelzad R et al (2017) Interventions for preventing cardiomyopathy due to anthracyclines: a Bayesian network meta-analysis. Ann Oncol 28(3):628–633. https://doi.org/10.1093/annonc/mdw671CrossRefPubMed

19.

Page MJ, Moher D (2017) Evaluations of the uptake and impact of the preferred reporting items for systematic reviews and Meta-analyses (PRISMA) statement and extensions: a scoping review. Syst Rev 6(1):263. https://doi.org/10.1186/s13643-017-0663-8CrossRefPubMedPubMedCentral

20.

Higgins JPGS (2011) Cochrane Handbook for systematic reviews of interventions version 5.1.0. [updated March 2011]. The Cochrane Collaboration (http:// www.cochrane-handbook.org.)

21.

Olivo SA, Macedo LG, Gadotti IC et al (2008) Scales to assess the quality of randomized controlled trials: a systematic review. Phys Ther 88(2):156–175. https://doi.org/10.2522/ptj.20070147CrossRefPubMed

22.

Jadad AR, Moore RA, Carroll D et al (1996) Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 17(1):1–12CrossRef

23.

Nabati M, Janbabai G, Baghyari S et al (2017) Cardioprotective effects of carvedilol in inhibiting doxorubicin-induced cardiotoxicity. J Cardiovasc Pharmacol 69(5):279–285. https://doi.org/10.1097/fjc.0000000000000470CrossRefPubMed

24.

Armenian SH, Hudson MM, Chen MH et al (2016) Rationale and design of the Children’s Oncology Group (COG) study ALTE1621: a randomized, placebo-controlled trial to determine if low-dose carvedilol can prevent anthracycline-related left ventricular remodeling in childhood cancer survivors at high risk for developing heart failure. BMC Cardiovasc Disord 16(1):187. https://doi.org/10.1186/s12872-016-0364-6CrossRefPubMedPubMedCentral

25.

Cardinale D, Colombo A, Lamantia G et al (2010) Anthracycline-induced cardiomyopathy: clinical relevance and response to pharmacologic therapy. J Am Coll Cardiol 55(3):213–220. https://doi.org/10.1016/j.jacc.2009.03.095CrossRefPubMed

26.

Bosch X, Rovira M, Sitges M et al (2013) Enalapril and carvedilol for preventing chemotherapy-induced left ventricular systolic dysfunction in patients with malignant hemopathies: the OVERCOME trial (preventiOn of left Ventricular dysfunction with Enalapril and caRvedilol in patients submitted to intensive ChemOtherapy for the treatment of Malignant hEmopathies). J Am Coll Cardiol 61(23):2355–2362. https://doi.org/10.1016/j.jacc.2013.02.072CrossRefPubMed

27.

Elitok A, Oz F, Cizgici AY et al (2014) Effect of carvedilol on silent anthracycline-induced cardiotoxicity assessed by strain imaging: A prospective randomized controlled study with six-month follow-up. Cardiol J 21(5):509–515. https://doi.org/10.5603/CJ.a2013.0150CrossRefPubMed

28.

El-Shitany NA, Tolba OA, El-Shanshory MR, El-Hawary EE (2012) Protective effect of carvedilol on adriamycin-induced left ventricular dysfunction in children with acute lymphoblastic leukemia. J Card Fail 18(8):607–613. https://doi.org/10.1016/j.cardfail.2012.06.416CrossRefPubMed

29.

Jhorawat R, Kumari S, Varma SC et al (2016) Preventive role of carvedilol in adriamycin-induced cardiomyopathy. Indian J Med Res 144(5):725–729. https://doi.org/10.4103/ijmr.IJMR_1323_14CrossRefPubMedPubMedCentral

30.

Kalay N, Basar E, Ozdogru I et al (2006) Protective effects of carvedilol against anthracycline-induced cardiomyopathy. J Am Coll Cardiol 48(11):2258–2262. https://doi.org/10.1016/j.jacc.2006.07.052CrossRefPubMed

31.

Liu L, Liu ZZ, Liu YY et al (2013) Preventive effect of low-dose carvedilol combined with candesartan on the cardiotoxicity of anthracycline drugs in the adjuvant chemotherapy of breast cancer. Zhonghua Zhong Liu Za Zhi 35(12):936–940PubMed

32.

Tashakori Beheshti A, Mostafavi Toroghi H, Hosseini G et al (2016) Carvedilol administration can prevent doxorubicin-induced cardiotoxicity: a double-blind randomized trial. Cardiology 134(1):47–53. https://doi.org/10.1159/000442722CrossRefPubMed

33.

Avila MS, Ayub-Ferreira SM, de Barros Wanderley JMR et al (2018) Carvedilol for prevention of chemotherapy related cardiotoxicity. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2018.02.049CrossRefPubMed

34.

Noutsias M, Maisch B (2011) Treatment of cardiovascular diseases in cancer patients. Herz 36(4):340–345. https://doi.org/10.1007/s00059-011-3452-5CrossRefPubMed

35.

Suter TM, Ewer MS (2013) Cancer drugs and the heart: importance and management. Eur Heart J 34(15):1102–1111. https://doi.org/10.1093/eurheartj/ehs181CrossRefPubMed

36.

Johnson CB, Sulpher J, Stadnick E (2015) Evaluation, prevention and management of cancer therapy-induced cardiotoxicity: a contemporary approach for clinicians. Curr Opin Cardiol. https://doi.org/10.1097/HCO.0000000000000145CrossRefPubMed

37.

Armstrong GT, Chen Y, Yasui Y et al (2016) Reduction in late mortality among 5‑year survivors of childhood cancer. N Engl J Med 374(9):833–842. https://doi.org/10.1056/NEJMoa1510795CrossRefPubMedPubMedCentral

38.

Patnaik JL, Byers T, DiGuiseppi C et al (2011) Cardiovascular disease competes with breast cancer as the leading cause of death for older females diagnosed with breast cancer: a retrospective cohort study. Breast Cancer Res 13(3):R64. https://doi.org/10.1186/bcr2901CrossRefPubMedPubMedCentral

39.

Murtagh G, Lyons T, O’Connell E et al (2016) Late cardiac effects of chemotherapy in breast cancer survivors treated with adjuvant doxorubicin: 10-year follow-up. Breast Cancer Res Treat 156(3):501–506. https://doi.org/10.1007/s10549-016-3781-4CrossRefPubMed

40.

Cohen-Solal A, Jacobson AF, Pina IL (2017) Beta blocker dose and markers of sympathetic activation in heart failure patients: interrelationships and prognostic significance. ESC Heart Fail 4(4):499–506. https://doi.org/10.1002/ehf2.12153CrossRefPubMedPubMedCentral

41.

Inampudi C, Alvarez P, Asleh R, Briasoulis A (2018) Therapeutic approach to patients with heart failure with reduced ejection fraction and end-stage renal disease. Curr Cardiol Rev. https://doi.org/10.2174/1573403X14666180123164916CrossRefPubMedPubMedCentral

42.

Guang-Yi C, Li-Sha G, Yue-Chun L (2018) Role of heart rate reduction in the management of myocarditis. Curr Pharm Des. https://doi.org/10.2174/1381612824666180111105923CrossRefPubMed

43.

Moher D, Pham B, Jones A et al (1998) Does quality of reports of randomised trials affect estimates of intervention efficacy reported in meta-analyses? Lancet 352(9128):609–613. https://doi.org/10.1016/s0140-6736(98)01085-xCrossRefPubMed

44.

Plana JC, Galderisi M, Barac A et al (2014) Expert consensus for multimodality imaging evaluation of adult patients during and after cancer therapy: a report from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. J Am Soc Echocardiogr 27(9):911–939. https://doi.org/10.1016/j.echo.2014.07.012CrossRefPubMed

45.

Thavendiranathan P, Grant AD, Negishi T et al (2013) Reproducibility of echocardiographic techniques for sequential assessment of left ventricular ejection fraction and volumes: application to patients undergoing cancer chemotherapy. J Am Coll Cardiol 61(1):77–84. https://doi.org/10.1016/j.jacc.2012.09.035CrossRefPubMed

46.

Rea D, Coppola C, Barbieri A et al (2016) Strain analysis in the assessment of a mouse model of cardiotoxicity due to chemotherapy: sample for preclinical research. In Vivo 30(3):279–290PubMed

47.

Migrino RQ, Aggarwal D, Konorev E et al (2008) Early detection of doxorubicin cardiomyopathy using two-dimensional strain echocardiography. Ultrasound Med Biol 34(2):208–214. https://doi.org/10.1016/j.ultrasmedbio.2007.07.018CrossRefPubMed

48.

Jurcut R, Wildiers H, Ganame J et al (2008) Strain rate imaging detects early cardiac effects of pegylated liposomal Doxorubicin as adjuvant therapy in elderly patients with breast cancer. J Am Soc Echocardiogr 21(12):1283–1289. https://doi.org/10.1016/j.echo.2008.10.005CrossRefPubMed

49.

Stoodley PW, Richards DA, Hui R et al (2011) Two-dimensional myocardial strain imaging detects changes in left ventricular systolic function immediately after anthracycline chemotherapy. Eur J Echocardiogr 12(12):945–952. https://doi.org/10.1093/ejechocard/jer187CrossRefPubMed

50.

Nagueh SF, Appleton CP, Gillebert TC et al (2009) Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr 10(2):165–193. https://doi.org/10.1093/ejechocard/jep007CrossRefPubMed

51.

Di Lisi D, Bonura F, Macaione F et al (2011) Chemotherapy-induced cardiotoxicity: role of the tissue Doppler in the early diagnosis of left ventricular dysfunction. Anticancer Drugs 22(5):468–472. https://doi.org/10.1097/CAD.0b013e3283443704CrossRefPubMed

52.

Danesi R, Del Tacca M, Soldani G (1986) Measurement of the S alpha T segment as the most reliable electrocardiogram parameter for the assessment of adriamycin-induced cardiotoxicity in the rat. J Pharmacol Methods 16(3):251–259CrossRef

53.

Jensen RA, Acton EM, Peters JH (1984) Doxorubicin cardiotoxicity in the rat: comparison of electrocardiogram, transmembrane potential, and structural effects. J Cardiovasc Pharmacol 6(1):186–200CrossRef

54.

Skrypnyk I, Maslova G, Lymanets T, Gusachenko I (2017) L‑arginine is an effective medication for prevention of endothelial dysfunction, a predictor of anthracycline cardiotoxicity in patients with acute leukemia. Exp Oncol 39(4):308–311CrossRef

55.

Shimomura Y, Baba R, Watanabe A et al (2011) Assessment of late cardiotoxicity of pirarubicin (THP) in children with acute lymphoblastic leukemia. Pediatr Blood Cancer 57(3):461–466. https://doi.org/10.1002/pbc.23012CrossRefPubMed

56.

Horacek JM, Jakl M, Horackova J et al (2009) Assessment of anthracycline-induced cardiotoxicity with electrocardiography. Exp Oncol 31(2):115–117PubMed

57.

Galetta F, Franzoni F, Cervetti G et al (2005) Effect of epirubicin-based chemotherapy and dexrazoxane supplementation on QT dispersion in non-Hodgkin lymphoma patients. Biomed Pharmacother 59(10):541–544. https://doi.org/10.1016/j.biopha.2004.12.003CrossRefPubMed

58.

Drafts BC, Twomley KM, D’Agostino R Jr. et al (2013) Low to moderate dose anthracycline-based chemotherapy is associated with early noninvasive imaging evidence of subclinical cardiovascular disease. JACC Cardiovasc Imaging 6(8):877–885. https://doi.org/10.1016/j.jcmg.2012.11.017CrossRefPubMedPubMedCentral

59.

Sawaya H, Sebag IA, Plana JC et al (2012) Assessment of echocardiography and biomarkers for the extended prediction of cardiotoxicity in patients treated with anthracyclines, taxanes, and trastuzumab. Circ Cardiovasc Imaging 5(5):596–603. https://doi.org/10.1161/circimaging.112.973321CrossRefPubMedPubMedCentral

60.

Jones M, O’Gorman P, Kelly C et al (2017) High-sensitive cardiac troponin-I facilitates timely detection of subclinical anthracycline-mediated cardiac injury. Ann Clin Biochem 54(1):149–157. https://doi.org/10.1177/0004563216650464CrossRefPubMed

61.

Wang YD, Chen SX, Ren LQ (2016) Serum B‑type natriuretic peptide levels as a marker for anthracycline-induced cardiotoxicity. Oncol Lett 11(5):3483–3492. https://doi.org/10.3892/ol.2016.4424CrossRefPubMedPubMedCentral

62.

Krum H (2004) Tolerability of carvedilol in heart failure: clinical trials experience. Am J Cardiol 93(9a):58b–63b. https://doi.org/10.1016/j.amjcard.2004.01.027CrossRefPubMed

63.

Kitakaze M, Sarai N, Ando H et al (2012) Safety and tolerability of once-daily controlled-release carvedilol 10–80 mg in Japanese patients with chronic heart failure. Circ J 76(3):668–674CrossRef

Titel: Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials
verfasst von: Dr. T. Zhan
Dr. M. Daniyal
Dr. J. Li
Dr. Y. Mao
Publikationsdatum: 17.01.2019
Verlag: Springer Medizin
Erschienen in: Herz / Ausgabe Sonderheft 1/2020
Print ISSN: 0340-9937
Elektronische ISSN: 1615-6692
DOI: https://doi.org/10.1007/s00059-018-4779-y

Neu im Fachgebiet Kardiologie

19.04.2024 | Vorhofflimmern | Nachrichten

Update Kardiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Preventive use of carvedilol for anthracycline-induced cardiotoxicity: a systematic review and meta-analysis of randomized controlled trials

Abstract

Background

Methods

Results

Conclusion

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Background

Methods

Results

Conclusion

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 1/2020

Stroke in patients with prosthetic valve endocarditis

Management of neoplastic pericardial disease

Alprostadil attenuates LPS-induced cardiomyocyte injury by inhibiting the Wnt5a/JNK/NF-κB pathway

Plasma osteopontin levels, but not its myocardial expression, reflect heart failure severity in recently diagnosed dilated cardiomyopathy

QTc interval prolongation during recovery from brief high-intensity intermittent exercise in obese adults

Prevalence of TTN mutations in patients with dilated cardiomyopathy

Neu im Fachgebiet Kardiologie

Parodontalbehandlung verbessert Prognose bei Katheterablation

Antihypertensiva schützen auch alte Menschen noch vor Demenz

Sind Betablocker auch für ältere herzschwache Personen nützlich?

Stillende Frauen haben geringeres kardiovaskuläres Risiko

Update Kardiologie